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Abstract
Melorheostosis (MEL) is an uncommon, sclerosing disease, characterised by hyperostosis of long bones, resembling the 
flowing of candle wax. The disease is sporadic and the pathogenesis is still poorly understood. Occasionally, the same family 
can include individuals with MEL and Osteopoikilosis (OPK), a disease characterised by multiple round foci of increased 
bone density. LEMD3 gene mutations are related to OPK and Buschke–Ollendorff Syndrome, a genetic condition in which 
an association between MEL, OPK and skin lesions is observed. In rare cases, LEMD3 mutations and recently mosaic 
MAP2K1 gene mutations have been correlated to MEL suggesting that somatic mosaicism could be causative of the disease. 
In this study, we described the clinical, radiological and molecular findings of 19 individuals with MEL and 8 with OPK 
and compared the results to the medical literature. The molecular analyses of this case series corroborate the available data 
in the medical literature, indicating that LEMD3 germline mutations are not a major cause of isolated MEL and reporting 
five further cases of OPK caused by LEMD3 germline mutations.
Keywords Melorheostosis · Osteopoikilosis · LEMD3 gene · Osteopoikilosis with or without melorheostosis
Introduction
Melorheostosis (MEL, OMIM #155950) [1] is an uncom-
mon sclerosing bone disease characterised by “flowing 
hyperostosis”, resembling the dripping of candle wax on 
the surface of the long bones. The distribution of the lesions 
is usually unilateral and asymmetric or corresponds to a par-
ticular sclerotome [1, 2].
According to the literature, no gender prevalence is 
observed and the disease might be diagnosed at all ages 
[3]. However, most cases are diagnosed around the age of 
20 years (50% of cases) [3]. In childhood or adolescence, 
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the progression of the bone lesions is variable and may 
lead to late diagnosis in adulthood [3]. There is a wide 
spectrum of clinical presentations, from asymptomatic 
cases to patients with chronic pain, joint stiffness, bone 
deformity, sometimes subcutaneous and soft tissues 
alterations [3–5].
The most frequently involved site is the appendicular 
skeleton (lower and upper limbs, hands and feet), with 
monostotic or polyostotic (or, rarely, bilateral) patterns [6]. 
Isolated MEL is usually a sporadic disease with no Men-
delian pattern of inheritance or defined pathogenesis. The 
available medical literature includes mainly case reports or 
small case series, describing clinical aspects and surgical 
approaches, but the majority of those studies do not report 
any molecular investigation [3, 6, 7].
Osteopoikilosis (OPK, OMIM #166700) is an inherited 
disorder, with autosomal dominant pattern of transmission, 
characterised by dense bony island appearing as bright 
lesions on radiographs. It has an estimated incidence of 
1:50,000 [8] and no gender differences. Since it is usually 
asymptomatic and only up to 20% of patients refers joint 
pain, the diagnosis of OPK is often an incidental finding 
on imaging studies performed for other health reasons [9, 
10].
OPK lesions can be either isolated, associated to MEL 
or part of Buschke–Ollendorff Syndrome (BOS, OMIM 
#166700). BOS is an autosomal dominant connective tissue 
disorder characterised by skin and bone manifestations [1]. 
In the literature, one study describes individuals with OPK 
and other with MEL in the same family [11].
LEMD3 protein (MAN antigen 1 MAN1) acts as antago-
nist of TGF-B signalling, and loss of function by LEMD3 
mutation can accelerate bone formation (OMIM *607844) 
[1, 2]. Germline mutations in LEMD3 gene have been related 
to a variable phenotypic spectrum, including isolated OPK, 
MEL with OPK and BOS [1, 2]. Due to the presence of 
LEMD3 mutations in familial cases of MEL with OPK, the 
role of the gene in the pathogenesis of isolated MEL has 
been postulated [5, 11]. Despite this, no germline mutations 
have been detected, and mosaic mutations were identified 
only in a few cases [12]. A recent study found no LEMD3 
mutations with whole exome sequencing of 15 patients, 
instead mosaic mutations in MAP2K1 gene were identified 
[13]. The importance of the MEK1-ERK1-2 in bone cell 
biology and in the disorder [13], as a role of somatic muta-
tions of KRAS gene, was advocated in the pathogenesis of 
the disease [2]. All these findings reinforce the hypothesis 
of mosaic mutation(s) as causative of MEL; nevertheless, 
further investigations are needed to confirm this.
In this study, we present a case series of 27 patients, 19 
with MEL and 8 with OPK. This is the largest Italian study 




All cases included in the study were selected according to 
clinical and radiological features of MEL or OPK. Patients of 
both gender and all ages were included. A study for clinical 
and molecular characterisation of skeletal rare diseases was 
approved by the Ethical Committee. Informed signed consent 
was obtained from all individual participants (or the parents 
in case of minors).
Molecular Analysis
Genomic DNA of all subjects was extracted from periph-
eral blood by using an automated workstation (Biomek NX, 
Beckman Coulter with Agencourt Genfind DNA isolation kit). 
DNA quality was checked with a NanoQuant Infinite M200 
instrument (Tecan Group Ltd, Männedorf, Switzerland) before 
analyses.
In 3 MEL patients, LEMD3 genetic screening has been also 
performed on DNA from cultured fibroblasts (one) or from 
soft and bone tissue around the lesions obtained in surgical 
intervention for reduction of calcifications (2), extracted using 
QIAamp DNA Mini kit(QIAGEN GmbH, Hilden, Germany).
For each DNA sample, screening of all coding exons and 
flanking exon–intron junctions of LEMD3 was performed by 
Sanger sequencing. All regions were PCR-amplified using 
Veriti 96-well thermal cycler by Thermo Fisher Scientific in 
a 30-µl volume. The results of amplification and the presence 
of right-sized PCR reaction products were confirmed by aga-
rose gel electrophoresis. Amplification products were then 
sequenced in both forward and reverse direction using Big-
Dye Terminator chemistry version 3.1 and ABI Prism 3130XL 
automated DNA sequencer (Thermo Fisher Scientific). The 
reference LEMD3 sequence was obtained from GenBank 
accession numbers NM_014319.3.
All samples without any LEMD3 point mutation were ana-
lysed with the use of Real-Time PCR technique for the occur-
rence of exon, multiexon deletions and duplications. Q-PCR 
was performed on a Corbett Rotor Gene 6000 instrument 
using SYBR Green Dye I chemistry (RT2 Real-Time SYBR 
Green PCR Mix, SABiosciences, Frederick, MD, USA). 
Human b-actin (NC_000007.12) was used as endogenous 
control; DNA from healthy individuals was used as calibrator 
(DDCt = 1; DDCt for deleted exons = 0.5; DDCt for duplicated 
exons = 2).
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Results
Our series included 19 patients with diagnosis of MEL and 8 
patients with diagnosis of OPK. Clinical data of MEL cases 
are described in Table 1.
Isolated MEL Group
This group included 19 patients and the diagnosis was per-
formed based on of the presence of candle wax hyperostosis 
at the radiological examination (Fig. 1). The majority of 
the patients were females (13/19 patients) and the age at 
the moment of data collection was between 6 and 62 years 
(mean: 33  years), ranging from 14 to 62  years (mean: 
35 years) in females and from 6 to 60 years in males (mean: 
29 years).
Data about the first clinical manifestations were avail-
able for 15 individuals and are shown in Fig. 2a and b. 
Recurrent pain at the site of hyperostosis was reported as 
first clinical manifestation in eight patients (six females 
and two males). The presence of deformities was referred 
Table 1  Clinical findings results 
and comparison to literature
a Cases with hand only involvement excluded
b Cases with foot only involvement excluded




Age at the first investigation/clinical manifestation All cases (18) All cases (23)
 0 to 18 years 5 (28%)
   > 18 years 3 (72%)
Gender All cases (19)
 Female 13 (68.4) 5 (79.2)
 Male 6 (31.6) 19 (20.8)
Affected site All cases (19)
 Head 0 2 (8.3)
 Spine 0 4 (16.6)
 Arm 2 (10.5) 8 (33.3)
 Hand or wrist 4 (21) 7 (29.1)
 Leg 11 (57.9) 16 (66.7)
 Ankle or foot 5 (26.3) 9 (37.5)
 Single limb 18 (94.7) 20 (83)
 Upper  limba 1 (5.3)
 Lower  limbb 10 (52.6)
 Only hand 4 (21)
 Only foot 3 (15.8)
 Both lower + upper limbs 1 (5.3)
 Upper limb + hand 5 (26.3)
 Lower limb + foot 13 (68.4)
 Both lower and upper limb + hand and foot 1 (5.3)
Cause leading to the first investigation All cases (15)
 Pain 8 (53) 20 (83.3)
 Deformity 2 (13.3) 13 (54.2)
 Functional limitation/stiffness 3 (20) 11 (45.8)
 Incidental diagnosis 2 (13.3)




Clinical findings at the moment of the evaluation All cases (17)
 Pain 15 (88)
 Deformity 6 (35.2)
 Functional limitation/stiffness 8 (47)
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in two females, whereas a female and two males had 
limitations of joint motion or stiffness. Only two cases (a 
male and a female) (13%) had an incidental diagnosis after 
X-rays were performed for different clinical indications.
Considering the age of the first clinical manifestations, 
only two male patients had the first disease investigation 
already during childhood, while 13/18 patients (11 females 
and 2 males) were adults; only three patients, all females, 
had the first manifestations in adolescence.
At the time of our evaluation, pain was the most fre-
quently reported clinical manifestation, referred by 15 (11 
females and 4 males) patients. Limitation of joint movement 
and/or stiffness was reported in 8 cases. Only 6 cases (5 
females and a male) had some grade of deformity related 
to hyperostosis.
Figure 3 shows the limb involvement by hyperostosis in 
19 MEL patients. In the majority of cases, (13 patients, 5 
males and 8 females), the hyperostosis affected the lower 
limbs. This included one female with hyperostosis areas 
limited to the foot. In one case, the pelvic bones were also 
involved, and in another one both pelvis and lower limbs, 
including feet, were involved. Upper limbs, including wrists 
or hands, were affected in 5 patients. The hand is the second 
most frequently involved site (4/19 patients, all females); 
only one male patient had hyperostosis in the upper limb but 
not in the hands. Only one patient had hyperostosis in both 
upper and lower limbs.
Skin manifestations were observed in two females. Both 
of them had skin thickness; in particular, one patient had cal-
cifications above the area of the skeletal lesion and the other 
one had a dyschromia. In this last case, molecular analysis 
was also performed on DNA from both cultured fibroblasts 
and bone tissue without detecting any LEMD3 mutation.
Connective tissue nevus or true sclerodermic phenotypes 
were not observed in our series.
No germline mutations in LEMD3 gene have been identi-
fied in this group of patients. In 3 cases, molecular analy-
sis was performed also from tissue samples and no somatic 
mutations of LEMD3 have been found in these samples.
Osteopoikilosis Group
Eight patients (six males and two females) had a radiological 
diagnosis of OPK (Fig. 4), four of them characterised by a 
positive family history for OPK. In this group, the mean age 
at our evaluation was 39 years (ranging from 16 to 53 years).
In one case, the onset of the disease was during child-
hood (about 10-year-old boy), in four patients during 
Fig. 1  Radiological image of a femur with candle wax hyperostosis
Fig. 2  a First clinical manifestation in patients aged ≥ 18 years. b First clinical manifestation in patients aged < 18 years
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adulthood (three males and a female with an age ranging 
from 41 to 53 years) and 3 during puberty (two males and 
a female 14 to 16 years old).
In five patients (three males and two females), the 
first investigations were performed for recurrent pain, in 
two cases (both males) the diagnosis was incidental. In 
one asymptomatic case, the diagnosis was performed by 
molecular analysis for a positive family history.
At the moment of data collecting, hyperostotic areas were 
in both lower and upper limbs in four patients, in lower limbs 
in two patients and in the pelvis in three cases. At the time 
of clinical evaluation, four patients reported pain; bone 
deformities or joint limitations were present in one case, 
and stiffness in two patients.
LEMD3 molecular analysis identified a germline path-
ologic mutation in five among eight patients affected by 
OPK, belonging to seven different families. In particular, 
we detected a heterozygous deletion of the whole gene in a 
patient, a splice site mutation (c.1628-2A > G) in a second 
one, a non-sense mutation (c.2032C > T; p.Arg678*) in a 
third one. The last two patients are relatives and carry a 
duplication (c.1754dup, p.Asn585Lysfs*15).
The patient carrying the whole gene deletion was an adult 
male with skin lesions; the clinical diagnosis was suspected 
during childhood after radiological investigation performed 
for lower limbs pain.
The splice site mutation c.1628-2A > G was not previ-
ously described in the medical literature and we identified 
this mutation in a woman diagnosed for OPK in adult age 
after clinical investigations requested for lower limb joint 
pain. She presented OPK areas around the left knee.
The c.2032C > T variant (p.Arg678*) has been previously 
described by Couto et al. [11] in two families. In our study, 
in the patient carrying the c.2032C > T mutation, the diag-
nosis was performed in adult age after evaluations for lower 
limbs pain. The radiographs showed hyperostotic spots typi-
cal of OPK in the lower limb (Fig. 4).
The last identified variant [c.1754dup mutation 
(p.Asn585Lysfs*15)] was not reported in main mutational 
databases (LOVD, Clinvar) to date and we found this muta-
tion in two Italian patients (father and son) affected by OPK 
in the lower limb; the disease was accidentally identified 
during X-rays performed for a suspected traumatic fracture. 
In both cases, further investigations showed typical hyper-
ostotic areas in hands, feet and pelvis.
Discussion
MEL and OPK are hyperostotic bone diseases, with clinical 
expression ranging from asymptomatic to recurrent pain, 
bone deformity or joint limitation. While the genetic basis 
of OPK has been defined, MEL pathogenesis is to this date 
largely unknown.
In this study, which includes the largest series of MEL 
patients in Italy evaluated for the presence of LEMD3 variant 
until now, we did not detect any LEMD3 germline mutation 
in the isolated MEL group.
The imaging appearance of both MEL and OPK is quite 
typical. Our results are consistent with literature, confirm-
ing that LEMD3 mutations do not seem to play a role in 
Fig. 3  Site of hyperostosis distribution in MEL cases
Fig. 4  X-ray showing hyperostotic spots on the lower limb of a 
patient with OPK
220 M. Gnoli et al.
1 3
isolated MEL. On the other hand, we identified a LEMD3 
pathological variant in 5 of 8 OPK patients. Thus, the radio-
logical diagnosis of OPK seems to be consistently associated 
with LEMD3 mutations and autosomal dominant form of 
the disease.
Isolated MEL is a sporadic disease, but because few fami-
lies with recurrence of MEL and/or OPK exist and the diag-
nosis can be incidental for the absence of clinical manifesta-
tion, molecular analysis can be the only tool to exclude an 
autosomal dominant form of the disease, even if this seems 
very rare.
Between our MEL cases, female gender was more preva-
lent (nearly 70%), and similar to the ratio of 4:1 female to 
male found by Smith et al. [6]. As highlighted by Smith 
et al., this finding contrasts the mosaicism hypothesis that 
would have no impact on gender, since both genders can be 
equally affected without predilection, unless the candidate 
genes are located on chromosome X.
The clinical expression of MEL was quite variable in our 
case series. According to literature data, MEL can be diag-
nosed at any age, but approximately 50% of the diagnoses 
are made around the age of 20 years. We observed that the 
first clinical suspicion occurred for most cases during adult-
hood (70%), and only about 30% of patients received the 
diagnosis before the adult age. A difference in the age of 
onset appears between the male and female groups: one-
third of the MEL patients had the first clinical manifestation 
in adolescence and they are all females. Furthermore, it is 
known that the diagnosis of MEL or OPK is often incidental 
but in this series few cases of MEL (about 13%) received 
the diagnosis after X-rays performed for other indications: 
pain, bone deformities or joint limitations were the reasons 
to medical investigations in most of the patients.
The main clinical manifestation observed was recurrent 
pain, which is consistent with literature. Lower limbs were 
the most common site involved, confirming the data from 
the series reported by Smith et al. [6]; no skull involvement 
was found. The disorder is nearly always monomelic; in a 
previous report, more than 80% of the cases had a single 
limb involvement, as this series, where only one case showed 
the disease in both lower and upper limbs. In particular, 
the bilateral distribution of the lesions in one case and the 
involvement of the upper and lower right limb in another one 
were in contrast with the sclerotomal hypothesis.
Jha et al. observed the same pattern of distribution in 
MEL by CT analysis in only a minority of the cases, stress-
ing the need for further studies to understand both aetiology 
and the causes for clinical variability in MEL [14].
In the eight patients with radiological diagnosis of OPK, 
we found a LEMD3 pathological variant in four patients and 
a whole gene deletion in one (more than 60% of detection 
rate). No evident genotype–phenotype correlation could be 
performed. The c.2032C > T(p.Arg678*) LEMD3 mutation 
has been previously described in two families with OPK and 
related to the disease; one is a third-generation family of 
Azorean origin (three members) and the other one is a small 
family of two members from Ireland [12]. As in the case we 
described, the molecular diagnosis was performed in adult 
age for the first family. The second family’s proband had the 
molecular diagnosis when she was 12 years old and showed 
OPK with MEL. From historical information and analysis 
of haplotype, the authors speculated a common founder in 
these two families.
The ethnic origin of the case reported here carrying the 
p.Arg678* mutation is in line with the origins of the popu-
lation in Azores, that is composed by different populations 
[15]. OPK involved a lower limb and the diagnosis was per-
formed after evaluation for lower limbs pain. X-ray showed 
hyperostosis spots in the lower limb, but not the typical can-
dle wax appearance of MEL.
In addition, a mutation that was not previously reported in 
main mutational databases, c.1754dup (p. Asn585Lysfs*15), 
was identified in two related patients, a father and a son. 
Interestingly, both of them had an almost asymptomatic dis-
ease and had similar unilateral distribution of the lesions, in 
both upper and lower limbs.
In the medical literature, a smaller stature has been 
reported in adults with OPK. In our series, even if we do 
not know the parental target, patients affected by OPK had a 
height below 50° percentile; in particular, three of them are 
around the 3° percentile of the Italian population, according 
to literature data [16]. For the best of our knowledge, none 
of our OPK patients underwent evaluation of developmental 
delay, which previously has been reported in as high percent-
age as 50% of patients with LEMD3 mutation [16].
A collecting bias should be considered in this study, since 
our department is part of a surgical orthopaedic institute. If 
the first manifestation is mild and related to skin involve-
ment around the skeletal lesions—as described in medical 
literature, especially in OPK—this rare condition could not 
be suspected at the beginning of the clinical presentation and 
the diagnosis can be missed. This would lead to a diagnostic 
delay at a specialised centre for rare skeletal diseases; in 
particular, the patient may not remember when the first clini-
cal signs began before the diagnosis of bone hyperostosis.
In conclusion, our clinical findings in the MEL and OPK 
series were in line with the medical literature, except for 
the low percentage of incidental diagnosis of MEL, that we 
found in only 10% of cases. A LEMD3 gene mutation has 
been found in more than 60% of OPK patients in our series. 
Instead, no alteration was identified in isolated MEL, con-
firming that other genes and mechanisms had to be involved 
in pathogenesis and variability of the disease. Thus, further 
investigations will be needed to clarify these aspects, that 
potentially will shed light into bone biology and therapies 
for other diseases affecting bone mass.
221Melorheostosis and Osteopoikilosis Clinical and Molecular Description of an Italian Case…
1 3
Acknowledgements We thank all the patients and their families for 
their participation in this study and the colleagues who contribute to 
this work. We are grateful to BIOGEN biobank, member of the Tel-
ethon Network of Genetic Biobanks and of the EuroBioBank network, 
which provided us with the biological samples.
Author Contributions MG designed the study and prepared the first 
draft of the paper. She had the main role in revising process for the 
final draft. She was also involved in the patients’ recruitment, in clini-
cal diagnosis and in the collection, revision and organisation of all 
clinical data. ELS, LC, MFB, FF, SG, AG, TM, FG, AP, IN, AV, MT, 
AM, EB and LS contributed to clinical diagnosis, collection of clini-
cal data and draft of the paper. EP performed molecular analysis and 
interpretation of molecular results and draft of the paper. All authors 
revised the paper critically for intellectual content and then approved 
the final version. All authors agree to be accountable for the work and 
to ensure the accuracy and integrity of the paper. All authors read and 
approved the final manuscript.
Compliance with Ethical Standards 
Conflict of interest Maria Gnoli, Eric Lodewijk Staals, Laura Cam-
panacci, Maria Francesca Bedeschi, Flavio Faletra, Salvatore Gal-
lone, Agostino Gaudio, Teresa Mattina, Fiorella Gurrieri, Antonio 
Percesepe, Iria Neri, Annalucia Virdi, Morena Tremosini, Annamaria 
Milanesi, Evelise Brizola, Elena Pedrini and Luca Sangiorgi declare 
that they have no conflict of interest.
Human and Animal Rights A study for clinical and molecular charac-
terization of skeletal rare diseases (Prot n. 21623 : “BIOGEN”; “Istituz-
ione di una Biobanca Genetica diagnostica e di ricerca presso la S.S.D. 
di Genetica Medica e Malattie Rare Ortopediche”) and amendments 
(Prot. gen. 0041207 and following,) were approved by the Ethical Com-
mittee of Istituto Ortopedico Rizzoli.
Informed Consent Informed signed consent was obtained from all indi-
vidual participants (or the parents in case of minors).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Online Mendelian Inheritance in Man, OMIM® (2018) McK-
usick-Nathans Institute of Genetic Medicine, Johns Hopkins 
University; Baltimore: 2018 World Wide Web. http://omim.org. 
Accessed 1 Dec 2018
 2. Whyte MP, Griffith M, Trani L, Mumm S, Gottesman GS, McAl-
ister WH, Krysiak K, Lesurf R, Skidmore ZL, Campbell KM, 
Rosman IS, Bayliss S, Bijanki VN, Nenninger A, Van Tine BA, 
Griffith OL, Melorheostosis MER (2017) Exome sequencing of 
an associated dermatosis implicates postzygotic mosaicism of 
mutated KRAS. Bone 101:145–155. https ://doi.org/10.1016/j.
bone.2017.04.010
 3. Kotwal A, Clarke BL (2017) Melorheostosis: a rare sclerosing 
bone dysplasia. Curr Osteoporos Rep 15(4):335–342. https ://doi.
org/10.1007/s1191 4-017-0375-y
 4. Freyschmidt J (2001) Melorheostosis: a review of 23 cases. Eur 
Radiol 11(3):474–479
 5. Hellemans J, Preobrazhenska O, Willaert A, Debeer P, Verdonk 
PC, Costa T, Janssens K, Menten B, Van Roy N, Vermeulen SJ, 
Savarirayan R, Van Hul W, Vanhoenacker F, Huylebroeck D, De 
Paepe A, Naeyaert JM, Vandesompele J, Speleman F, Verschueren 
K, Coucke PJ, Mortier GR (2004) Loss-of-function mutations in 
LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome 
and melorheostosis. Nat Genet 36:1213–1218
 6. Smith GC, Pingree MJ, Freeman LA, Matsumoto JM, Howe BM, 
Kannas SN, Pyfferoen MD, Struss LT, Wenger DE, Amrami KK, 
Matsumoto M, Jurisson ML (2017) Melorheostosis: a retrospec-
tive clinical analysis of 24 patients at the Mayo Clinic. PMR 
9(3):283–288. https ://doi.org/10.1016/j.pmrj.2016.07.530
 7. Gagliardi GG, Mahan KT (2010) Melorheostosis: a literature 
review and case report with surgical considerations. J Foot Ankle 
Surg 49(1):80–85
 8. Ng C, Schwartzman L, Moadel R, Haigentz M Jr (2015) Oste-
opoikilosis: a benign condition with the appearance of meta-
static bone disease. J Clin Oncol 33(18):e77–e78. https ://doi.
org/10.1200/JCO.2013.50.5222
 9. Tsai SY, Wang SY, Shiau YC, Wu YW (2016) Benign inciden-
tal findings of osteopoikilosis on Tc-99 m MDP bone SPECT/
CT: a case report and literature review. Medicine (Baltimore) 
95(23):e3868
 10. Boulet C, Madani H, Lenchik L, Vanhoenacker F, Amalnath DS, 
de Mey J, De Maeseneer M (2016) Sclerosing bone dysplasias: 
genetic, clinical and radiology update of hereditary and non-
hereditary disorders. Br J Radiol 89(1062):20150349. https ://doi.
org/10.1259/bjr.20150 349
 11. Couto AR, Bruges-Armas J, Peach CA, Chapman K, Brown MA, 
Wordsworth BP, Zhang Y (2007) A novel LEMD3 mutation com-
mon to patients with osteopoikilosis with and without melorhe-
ostosis. Calcif Tissue Int 81(2):81–84
 12. Zhang Y, Castori M, Ferranti G, Paradisi M, Wordsworth BP 
(2009) Novel and recurrent germline LEMD3 mutations causing 
Buschke-Ollendorff syndrome and osteopoikilosis but not isolated 
melorheostosis. Clin Genet 75(6):556–561. https ://doi.org/10.111
1/j.1399-0004.2009.01177 .x
 13. Kang H, Jha S, Deng Z, Fratzl-Zelman N, Cabral WA, Ivovic A, 
Meylan F, Hanson EP, Lange E, Katz J, Roschger P, Klaushofer 
K, Cowen EW, Siegel RM, Marini JC, Bhattacharyya T (2018) 
Somatic activating mutations in MAP2K1 cause melorheostosis. 
Nat Commun 9(1):1390. https ://doi.org/10.1038/s4146 7-018-
03720 -z
 14. Jha S, Laucis N, Kim L, Malayeri A, Dasgupta A, Papadakis GZ, 
Karantanas A, Torres M, Bhattacharyya T (2018) CT analysis 
of anatomical distribution of melorheostosis challenges the scle-
rotome hypothesis. Bone 117:31–36. https ://doi.org/10.1016/j.
bone.2018.09.005
 15. Santos C, Lima M, Montiel R, Angles N, Pires L, Abade A, Aluja 
MP (2003) Genetic structure and origin of peopling in the Azores 
islands (Portugal): the view from mtDNA. Ann Hum Genet 67(Pt 
5):433–456
 16. Pope V, Dupuis L, Kannu P, Mendoza-Londono R, Sajic D, 
So J, Yoon G, Lara-Corrales I (2016) Buschke-Ollendorff syn-
drome: a novel case series and systematic review. Br J Dermatol 
174(4):723–729. https ://doi.org/10.1111/bjd.14366 
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
